Clinical Trials
Study Title:
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
|
For more information about the trial above please contact the study team:
Medical University of South Carolina
Principal Investigator, Jacqueline Kraveka, at kravekjm@musc.edu.
Study Coordinator, Hannah Kinder, at kinderh@musc.edu.
Trial opened at the following institutions: Medical University of South Carolina |